Latham & Watkins Advises a Consortium Consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their Portfolio Company eResearchTechnologies in its Merger with Bioclinica, a Portfolio Company of Cinven

Cross-border, multidisciplinary team advised on the transaction.

December 11, 2020

ERT, a global leader in clinical end-point data solutions, has announced that Bioclinica, a technological and scientific leader in clinical imaging, has agreed to merge with eResearchTechnologies (ERT). This combination will create a leading partner to global pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, digital innovation and an unrelenting focus on customer service. The proposed transaction is subject to customary closing conditions, including approval by regulatory agencies. ERT and Bioclinica expect the transaction to close in 2021.

Latham & Watkins LLP represents a consortium consisting of Astorg Asset Management, Nordic Capital, Novo Holdings and their portfolio company ERT in the transaction with a corporate team led by New York partner David Beller, London/Paris partner Thomas Forschbach, and Houston partner Lauren Anderson, with associates Sašo Kraner, Karen Song, Trevor Kim, Samantha Seley, Michael Basist, and Daisy Clifton-Lee. Advice was also provided on tax matters by partner New York partner Matthew Dewitz, with associate Shruti Hazra; on benefits and compensation matters by Washington, D.C. partner Adam Kestenbaum, with associates Nikhil Kumar and Victoria Wolfe; on labor matters by Chicago counsel Nineveh Alkhas, with associate Laura Waller; on finance matters by New York partner Scott Ollivierre; on antitrust matters by Washington, D.C. partners Mandy Reeves and Jason Cruise and counsels Tomas Nilsson, Jana Dammann de Chapto, and Jason Daniels, with associate Niklas Brüggemann; on healthcare regulatory matters by Hamburg partner Christoph Engeler and Los Angeles counsel Jennifer Yoo, with associates Alyssa Lattner and Jaschar Mirkhani; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associates Barrett Tenbarge and Julie Shin; on intellectual property matters by New York partner Steven Betensky and New York counsel Carrie Girgenti, with associate Max Miroff; on data privacy and security matters by London partner Gail Crawford and Bay Area counsel Robert Blamires, with associates Jimmy Smith, Oliver Mobasser, and Victoria Wan; on real estate matters by New York counsel Shira Bressler, with associate Michael Nieberg; on EHS and ESG matters by London partner Paul Davies and counsels David Langer and Michael Green; on anti-corruption matters by Washington, D.C. counsel Timothy McCarten and London counsel Daniel Smith, with associate Cassie Martin; on trade controls matters by Washington, D.C. partner Les Carnegie and Washington, D.C. counsel Rachel Alpert, with associate Julie Shin; on insurance matters by Los Angeles partner Drew Levin, with associate Harrison White; on certain German law matters by Munich partners Sebastian Pauls and Tobias Leder, Frankfurt partner Susan Kempe-Mueller and Hamburg partner Otto von Gruben and Frankfurt counsel Joachim Grittmann, with associates Andreas Holzgreve, Kristina Steckermeier, Pia Sophie Sösemann, Jana Maue, Alexander Wilhelm, and Tarik Arabi; on certain UK law matters by London partner Catherine Drinnan and London counsel Michael Beanland, with associates Alex McCarney, Suneel Basson-Bhatoa, and Nick Fisher; and on certain French law matters by Paris partner Matthias Rubner.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.